Redeye: Moberg Pharma - Major inflection points approaching

Report this content

The recently announced agreements in Asia brings further external validation of MOB-015 as a promising new topical treatment of onychomycosis, boosting our conviction about the case ahead of the first top-line results expected in December. The share price has performed strongly in 2019 (+78%), but we see further upside for the stock before the top-line results.

Read more and download the Research Update:

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.